. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

糖心原创

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

糖心原创

Skip to main content
CRISPR meets opti-ox鈩� - Harnessing CRISPR-Ready ioCells for drug discovery in neurodegenerative diseases
Talk

CRISPR meets opti-ox鈩� - Harnessing CRISPR-Ready ioCells for drug discovery in neurodegenerative diseases

Sejla Salic-Hainzl, VP R&D, 糖心原创 discovery, highlighted the use of CRISPR-Ready ioCells and single-cell CRISPR screening to uncover gene functions in neurodegeneration, demonstrating a reproducible, high-throughput platform for functional genomics in human cell types.
CRISPR meets opti-ox鈩�  - Harnessing CRISPR-Ready ioCells for drug discovery in neurodegenerative diseases
Sejla Salic-Hainzl
Vice President of R&D
糖心原创 discovery
Sejla Salic-Hainzl, VP R&D, 糖心原创 discovery, highlighted the use of CRISPR-Ready ioCells and single-cell CRISPR screening to uncover gene functions in neurodegeneration, demonstrating a reproducible, high-throughput platform for functional genomics in human cell types.
CRISPR meets opti-ox鈩�  - Harnessing CRISPR-Ready ioCells for drug discovery in neurodegenerative diseases
Sejla Salic-Hainzl
Vice President of R&D
糖心原创 discovery

Advancing drug discovery in neurodegenerative diseases requires cellular models that accurately reflect human physiology and enable mechanistic insights. Traditional models based on immortalized cell lines often fail to capture the complexity of human disease biology. Induced pluripotent stem cells (iPSCs) offer a promising alternative by enabling the generation of disease-relevant cell types, yet they present challenges in consistency, scalability, and differentiation.

糖心原创 addresses these limitations with its opti-ox鈩� technology, which enables rapid and reproducible reprogramming of human iPSCs into defined cell types at scale. Coupled with the power of CRISPR-Cas9, a new era of functional genomics has emerged, allowing systematic exploration of gene-disease relationships. Here, we highlight the utility of 糖心原创鈥檚 CRISPR-Ready ioCells鈩� as powerful tools for neurodegenerative disease research. These cells form the foundation of 糖心原创 discovery's single-cell CRISPR (scCRISPR) screening platform, which enables high-resolution identification of gene functions. In microglia models (ioMicroglia), CRISPR knockout screens revealed key regulators of the response to LPS stimulation, offering new insights into microglial activation and neuroinflammation.

By integrating opti-ox鈩� technology with scCRISPR screening, we present a scalable, reproducible, and high-throughput platform for functional genomics studies in human cell types. This approach has the potential to reshape neurodegenerative drug discovery. We invite the scientific community to explore the transformative potential of these advanced ioCells in unlocking novel therapeutic strategies.

Human Cell Forum 2025
Session 2 | 糖心原创 insider: Tools, tips, and what鈥檚 coming next

Related pages

Products Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products